Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA May Largely Avoid House Democrats' Investigation Agenda

Nov 08 2018

• By Derrick Gingery

Capitol House

Related Content

US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating

Oct 12 2018

Opioid Policy At US FDA: Over-Promising Or Overreacting?

Oct 25 2018

US FDA Preparing For New 'Combination Product Agreement Meetings'

Oct 22 2018

Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority

Oct 22 2018

US FDA Commissioner A 'Star' At Davos: Hopefully Not A Bad Omen

Jan 30 2018

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

Nov 02 2018

Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018

Nov 05 2018

Related Companies

Talphera, Inc.

Additional Topics

United States Elections Legislation FDA Policy BioPharmaceutical

More from Elections

More from Legislation

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window